IP Library Granted Patent US 10,648,013
Granted Patent B2
US 10,648,013 · App. 16/387,992 · Granted May 12, 2020

Compounds and methods for detection of enzymes that remove formyl, succinyl, methyl succinyl or myristoyl groups from epsilon-amino lysine moieties

Inventors: Konrad T. Howitz (Allentown, PA); Zhongda Zhang (Wynnewood, PA); Anne Kisielewski (Wilmington, DE); Elizabeth Dale (Allentown, PA); Wayne Forrest Patton (Dix Hills, NY)
Assignee: Enzo Life Sciences, Inc.
C12Q1/34C07D311/16C07D493/10C12Y305/01098G01N2333/98
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,648,013
App. No.
16/387,992
Granted
May 12, 2020
Kind
B2
Abstract

Provided is a compound that comprises the structure: where SIG is a signaling molecule and R 3 is a formyl, a succinyl, a methyl succinyl, or a myristoyl. Also provided is a kit is provided that comprises the above compound, with instructions for determining the presence of the enzyme. Additionally, a method is provided for determining whether a sample has an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ε-amino of a lysine. Also provided is a method of determining whether a molecule inhibits an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ε-amino of a lysine.

Claims (29)

1. A method of determining whether at least one molecule inhibits an enzyme that removes a formyl moiety from an ε-amino of a lysine, the method comprising:

(a) mixing the enzyme and a molecule with a compound having the formula

wherein

SIG is a fluorophore or luminescent moiety, and

m is an integer from 1 to 10;

(b) incubating the enzyme-molecule-compound mixture to allow the enzyme to remove the formyl moiety in the absence of the molecule; and

(c) determining whether the formyl moiety is removed from the compound to an equivalent degree that the formyl moiety would be removed from the compound in the absence of the molecule,

wherein the failure of the removal of the formyl moiety from the compound to an equivalent degree as in the absence of the molecule indicates that the molecule is an inhibitor of the enzyme.

2. The method of claim 1 , wherein the enzyme is a histone deacetylase (HDAC).

3. The method of claim 1 , wherein the compound is a substrate for a peptidase after the enzyme cleaves the formyl moiety from the compound but not if the formyl moiety is not removed from the compound;

wherein the determining step further comprises

(i) adding the peptidase to the mixture to allow the peptidase to cleave the resulting molecule between the nitrogen bound to SIG and the carbonyl carbon bound to said nitrogen, such that SIG generates an increased signal relative to the signal generated with the compound; and

(ii) determining whether SIG generates an increased signal relative to the signal generated with the compound,

wherein an increased signal indicates the removal of the formyl moiety from the compound.

4. The method of claim 3 , wherein the peptidase is a trypsin.

5. The method of claim 3 , wherein the enzyme is a histone deacetylase (HDAC).

6. The method of claim 5 , wherein the peptidase is a trypsin.

7. The method of claim 1 , wherein SIG is a fluorophore.

8. The method of claim 1 , wherein SIG is a luminescent moiety.

9. The method of claim 2 , wherein SIG is a fluorophore.

10. The method of claim 2 , wherein SIG is a luminescent moiety.

11. The method of claim 3 , wherein SIG is a fluorophore.

12. The method of claim 3 , wherein SIG is a luminescent moiety.

13. The method of claim 1 , wherein the compound is

14. The method of claim 2 , wherein the compound is

15. The method of claim 3 , wherein the compound is

16. The method of claim 1 , wherein a plurality of different molecules are subjected to the method simultaneously.

17. The method of claim 2 , wherein a plurality of different molecules are subjected to the method simultaneously.

18. The method of claim 3 , wherein a plurality of different molecules are subjected to the method simultaneously.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2023
From: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
To: ENZO BIOCHEM, INC.; ENZO CLINICAL LABS, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP; ENZO LIFE SCIENCES, INC.
Reel/Frame 064369/0031 →
SECURITY INTEREST Recorded Apr 3, 2023
From: ENZO LIFE SCIENCES, INC.; ENZO CLINICAL LABS, INC.; ENZO BIOCHEM, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP
To: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
Reel/Frame 063239/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2019
From: HOWITZ, KONRAD T.; ZHANG, ZHONGDA; KISIELEWSKI, ANNE; DALE, ELIZABETH; PATTON, WAYNE FORREST
To: ENZO LIFE SCIENCES, INC.
Reel/Frame 049497/0663 →
Continuity (4)
Division 15944336 · Apr 3, 2018
Division 15464966 · Mar 21, 2017
Division 12930693 · Jan 13, 2011
Related Publication 20190338336A1 · Nov 7, 2019